glial growth factor 2
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01258387)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Pro-neuregulin-1, membrane-bound isoformSupplementation
NRG1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039542 ↗
Also known as
- cimaglermin alfa
- fibromatosis, gingival, 2
- fibromatosis, gingival, hereditary, 2
- ggf2
- ggf2
- ggf2
- ggf2
- ggf2
- gingf2
- glial growth facot 2
- glial growth factor 2
- hgf2
- rhggf2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01944683 | Phase 1 | Sep 1, 2013 | Acorda Therapeutics |
| NCT01258387 | Phase 1 | Dec 1, 2010 | Acorda Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Acorda Therapeutics | For profit | 2 | 2 | 1 | 2010 |
1 organizations
Page 1 / 1